Lancet Neurology
Papers 4550
1 page of 455 pages (4,550 results)
#1Meng-Chuan LaiH-Index: 32
#2Evdokia Anagnostou (U of T: University of Toronto)H-Index: 38
Last. Simon Baron-Cohen (University of Cambridge)H-Index: 2
view all 5 authors...
Summary Autism is both a medical condition that gives rise to disability and an example of human variation that is characterised by neurological and cognitive differences. The goal of evidence-based intervention and support is to alleviate distress, improve adaptation, and promote wellbeing. Support should be collaborative, with autistic individuals, families, and service providers taking a shared decision-making approach to maximise the individual's potential, minimise barriers, and optimise th...
2 CitationsSource
#1Kristelle Hudry (La Trobe University)H-Index: 21
#2Elizabeth Pellicano (Macquarie University)H-Index: 30
Last. Andrew J. O. Whitehouse (UWA: University of Western Australia)H-Index: 37
view all 4 authors...
#1Hugues Chabriat (Paris Diderot University)H-Index: 52
#2Claudio L. BassettiH-Index: 76
Last. Sergi AmaroH-Index: 1
view all 102 authors...
Summary Background S44819, a selective GABAA α5 receptor antagonist, reduces tonic post-ischaemic inhibition of the peri-infarct cortex. S44819 improved stroke recovery in rodents and increased cortical excitability in a transcranial magnetic stimulation study in healthy volunteers. The Randomized Efficacy and Safety Trial of Oral GABAA α5 antagonist S44819 after Recent ischemic Event (RESTORE BRAIN) aimed to evaluate the safety and efficacy of S44819 for enhancing clinical recovery of patients ...
1 CitationsSource
#1Matthew J. Rowland (University of Oxford)H-Index: 11
#2Tonny Veenith (University of Birmingham)H-Index: 9
Last. Gavin D. Perkins (Warw.: University of Warwick)H-Index: 56
view all 4 authors...
#1Jeremy Chataway (NIHR: National Institute for Health Research)H-Index: 28
#2Floriana De Angelis (UCL: University College London)H-Index: 7
Last. Ferran Prados CarrascoH-Index: 1
view all 51 authors...
Summary Background Neurodegeneration is the pathological substrate that causes major disability in secondary progressive multiple sclerosis. A synthesis of preclinical and clinical research identified three neuroprotective drugs acting on different axonal pathobiologies. We aimed to test the efficacy of these drugs in an efficient manner with respect to time, cost, and patient resource. Methods We did a phase 2b, multiarm, parallel group, double-blind, randomised placebo-controlled trial at 13 c...
1 CitationsSource
#1Ankur Khajuria (University of Oxford)H-Index: 7
#1S Winkler (TUM: Technische Universität München)H-Index: 28
#1Robert J. Fox (Cleveland Clinic)H-Index: 37
#1Valery L. Feigin (AUT: Auckland University of Technology)H-Index: 73
#2E. Theo Vos (UW: University of Washington)H-Index: 107
Last. Christopher Margono (UW: University of Washington)H-Index: 162
view all 10 authors...
Summary Neurological disorders are the leading cause of disability and the second leading cause of death worldwide. In the past 30 years, the absolute numbers of deaths and people with disabilities owing to neurological diseases have risen substantially, particularly in low-income and middle-income countries, and further increases are expected globally as a result of population growth and ageing. This rise in absolute numbers of people affected suggests that advances in prevention and management...
3 CitationsSource
Top fields of study
Physical therapy